Haverkamp
W, Shenasa M, Borggrefe M, Breithardt
G:
Torsades de Pointes.
In: Zipes DP, Jalife J (eds): Cardiac
Electrophysiology - From Cell to Bedside (2nd edition). WB Saunders
Company, Philadelphia 1995; 886-899. |
|
Reinhardt
L, Mäkijärvi M, Fetsch T, Sierra
G, Martinez-Rubio A, Montonen J, Katila T, Borggrefe M, Breithardt
G:
Non-invasive risk modeling after myocardial
infarction.
Am J Cardiol, 1996; 78: 627-632.
Abstract |
|
Reinhardt L , Mäkijärvi M, Fetsch T, Martinez-Rubio
A, Böcker D,Block M, Borggrefe M, Breithardt G:
Reduced beat-to-beat changes of heart
rate: an important risk factor after acute myocardial infarction.
Cardiology 1996; 87: 104-111.
Abstract |
|
Reinhardt L , Mäkijärvi M, Fetsch T, Montonen
J, Sierra G, Martinez-Rubio A, Katila T, Borggrefe M, Breithardt
G:
Predictive value of wavelet correlation
functions of the signal-averaged ECG in patients after anterior
and inferior myocardial infarction.
J Am Coll Cardiol 1996; 27: 53-59.
Abstract |
|
Reinhardt L , Vesanto R, Montonen J, Fetsch
T, Mäkijärvi M, Sierra G, Katila T, Breithardt G:
Localisation of myocardial infarction
based on Learning Vector Quantization networks applied to ST-elevations
of the 12-lead ECG.
Ann Noninvas Electrocardiol, 1997;
2: 331-337. |
|
Eckardt,
L, Haverkamp W,
Borggrefe, M, and Breithardt, G:
Experimental models of torsade de pointes.
Cardiovasc Res 1998; 39:178-183. Abstract |
|
Priori
SG, Barhanin J, Hauer RN, Haverkamp W , Jongsma HJ, Kleber AG, McKenna
WJ, Roden DM, Rudy Y, Schwartz K, Schwartz PJ, Towbin JA, Wilde
A:
Genetic and molecular basis of cardiac
arrhythmias; impact on clinical management. Parts I and II.
Circulation 1999; 99:518-528.
Abstract |
|
Priori
SG, Barhanin J, Hauer RN, Haverkamp W , Jongsma HJ, Kleber AG, McKenna
WJ, Roden DM, Rudy Y, Schwartz K, Schwartz PJ, Towbin JA, Wilde
A:
Genetic and molecular basis of cardiac
arrhythmias; impact on clinical management. Part III.
Circulation 1999; 99:674-681. |
|
Haverkamp W , Breithardt G, Janse MJ, Camm
AJ, Rosen MR, Antzelevitch C, Escande D, Franz M, Malik M, Moss
A, Shah R, and the other speakers in the sessions and the chairs
of the workshops:
The potential for QT prolongation by
non-antiarrhythmic drugs.
Clinical and regulatory implications.
Report on a policy conference of the European Society of cardiology.
Eur Heart J 2000; 21:1216-1231. |
|
Haverkamp W , Mönnig G, Schulze-Bahr E, Haverkamp F, Breithardt G:
Physician-induced Torsade de Pointes
- therapeutic implications.
Cardiovasc Drugs Ther. 2002; 16:101-109.
Abstract |
|
|
Haverkamp W, Haverkamp F , Breithardt G:
Medikamenten-bedingte QT-Verlängerung
und Torsade de Pointes: Ein multidisziplinäres Problem.
Deutsches Ärzteblatt, 2002; 99: B1662-B1668.
Full text |
|
Smits
JP, Eckardt L, Probst V, Bezzina CR, Schott JJ, Remme CA, Haverkamp W,
Breithardt G, Escande D, Schulze-Bahr E, LeMarec H, Wilde AA.:
Genotype-phenotype relationship in Brugada
syndrome: electrocardiographic features differentiate SCN5A-related
patients from non-SCN5A-related patients.
J Am Coll Cardiol. 2002; 40:350-356.
Abstract |
|
Milberg
P, Eckardt L, Bruns HJ, Biertz J, Ramtin S, Reinsch N, Fleischer
D, Kirchhof P, Fabritz L, Breithardt G, Haverkamp W:
Divergent proarrhythmic potential of
macrolide antibiotics despite similar QT prolongation: fast
phase 3 repolarization prevents early afterdepolarizations and
torsade de pointes.
J Pharmacol Exp Ther. 2002; 303:218-225.
Abstract |
|
Simelius
K, Stenroos M, Reinhardt L , Nenonen J, Tierala I, Mäkijärvi
M, Toivonen L, Katila T:
Spatiotemporal characterization of paced
cardiac activation with body surface potential mapping and self-organizing
maps.
Physiol Meas, 2003; 24: 805-816.
Abstract |
|
Paulussen
AD, Gilissen RA, Armstrong M, Doevendans PA, Verhasselt P, Smeets
HJ, Schulze-Bahr E, Haverkamp W , Breithardt G, Cohen N, Aerssens
J:
Genetic variations of KCNQ1, KCNH2, SCN5A,
KCNE1, and KCNE2 in drug-induced long QT syndrome patients.
J Mol Med 2004; 82:182-188.
Abstract |
|
Milberg
P, Ramtin S, Mönnig G, Osada N, Wasmer K, Breithardt G, Haverkamp W,
Eckardt L:
Comparison of the in vitro electrophysiologic
and proarrhythmic effects of amiodarone and sotalol in a rabbit
model of acute atrioventricular block.
J Cardiovasc Pharmacol 2004; 44:278-286.
Abstract |
|
Milberg
P, Reinsch N, Osada N, Wasmer K, Mönnig G, Stypmann J, Breithardt
G, Haverkamp W,
Eckardt L:
Verapamil prevents torsade de pointes
by reduction of transmural dispersion of repolarization and
suppression of early afterdepolarizations in an intact heart
model of LQT3.
Basic Res Cardiol. 2005; 100:365-71.
Abstract |
|
Titier
K, Girodet PO, Verdoux H, Molimard M, Begaud B, Haverkamp W , Lader M, Moore N:
Atypical antipsychotics: from potassium
channels to torsade de pointes and sudden death.
Drug Saf 2005; 28:35-51.
Abstract |
|
|
Reinhardt L, Haverkamp W:
Herzfrequenzkorrektur des QT-Intervalls
nach Bazett: Mythos oder Logos ?
Deutsche Zeitschrift für klinische
Forschung 3/4-2006; 61-63. |
|
Haverkamp W , Deuschle M:
Antipsychotikainduzierte QT-Verlängerung.
Der Nervenarzt 2006; 77:276-288.
Abstract |
|
Milberg
P, Fleischer D, Stypmann J, Osada N, Mönnig G, Engelen MA, Bruch
C, Breithardt G, Haverkamp W , Eckardt L:
Reduced repolarization reserve due to
anthracycline therapy facilitates torsade de pointes induced
by I(Kr) blockers.
Basic Res Cardiol. 2006 Jul 4; [Epub
ahead of print].
Abstract |
|
Wedekind
H, Bajanowski T, Friederich P, Breithardt G, Wulfing T, Siebrands
C, Engeland B, Mönnig G, Haverkamp W , Brinkmann B, Schulze-Bahr E:
Sudden infant death syndrome and long
QT syndrome: an epidemiological and genetic study.
Int J Legal Med. 2006 May; 120(3):129-37. Epub 2005 Jul 13.
Abstract |
|
Haverkamp W:
Congenital long QT syndrome.
Herz 2007 May; 32(3): 201-205. Review
Abstract |
|
Blaschke D, Parwani AS, Huemer M, Rolf S, Boldt LH, Dietz R, Haverkamp W:
Torsade de pointes during combined treatment with risperidone and citalopram.
Pharmacopsychiatry. 2007 Nov;40(6):294-5.
Abstract |
|
Bass AS, Darpo B, Breidenbach A, Haverkamp W, et al.:
International Life Sciences Institute (Health and Environmental Sciences Institute, HESI) initiative on moving towards better predictors of drug-induced torsades de pointes.
Br J Pharmacol 2008;154:1491-1501.
Abstract |
|
Huemer M, Boldt LH, Rolf S, Blaschke D, Parwani A, Haverkamp W:
Sustained monomorphic ventricular tachycardia after adenosine infusion.
Int J Cardiol 2009;131(3):e97-100.
Abstract |
|
Posch MG, Perrot A, Geier C, Haverkamp W, et al.:
Genetic deletion of arginine 14 in phospholamban causes dilated cardiomyopathy with attenuated electrocardiographic R amplitudes.
Heart Rhythm. 2009 Apr;6(4):480-6.
Abstract |
|
Zellerhoff S, Pistulli R, Mönnig G, Haverkamp W, et al.:
Atrial Arrhythmias in long-QT syndrome under daily life conditions: a nested case control study.
J Cardiovasc Electrophysiol. 2009 Apr;20(4):401-7.
Abstract |
|
|